ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
... syndrome. At the end of 2008, we completed a Phase IIb clinical study for ecabet sodium and believe the recently announced positive results, in addition to ...esigns and NDA filing requirements. Based upon our further analysis of the ecabet sodium Phase II data and results from our Xibrom lower concentration study,...ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
...Bepreve in the second half of 2009. With regard to ecabet sodium, our candidate for the treatment of dry eye...ing the decision to initiate Phase III trials with ecabet sodium. "Finally, we are noticing that the FDA i...er this year or in early 2009, the announcement of ecabet sodium preliminary Phase II top-line results, ISTA...ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
IRVINE, Calif., Jan. 22 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced positive results from the Company's Phase IIb clinical study of ecabet sodium, which is being developed as a treatment for dry eye disease. Patients treated with ecabet sodium achieved ...ISTA Pharmaceuticals Announces Positive Preliminary Results from Ecabet Sodium Phase IIb Study
... a treatment for dry eye syndrome. Patients in the ecabet sodium group achieved a strong trend in the object...e sign of blink rate. In addition, patients in the ecabet sodium group reported a strong trend in the Ocular...sed to confirm observations from previous clinical ecabet sodium studies and to serve as indicators of poten...ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
...nounce in the second half of 2008 top-line data results from our additional ecabet sodium Phase II study that we initiated earlier this year." ...dditional T-Pred studies later this year or early 2009, the announcement of ecabet sodium Phase II top-line results, ISTA's expectation of bringing a new prod...ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
...ement in redness and initiated both the Bepreve ocular safety study and the second Phase III study -- Announced positive results from the ecabet sodium Phase IIb study for the treatment of dry eye syndrome -- Successfully completed $36.7 million financing through the private placem...